{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:24:03Z","timestamp":1778617443692,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04776-8","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:31:11Z","timestamp":1775007071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fibrotic, metabolic and clinical improvements in patients with chronic hepatitis C treated with direct-acting antiviral therapy in a resource limited setting: a prospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Kinfe Woldu","family":"Ekubazgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miftah","family":"Dellil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beshada Zerfu","family":"Woldegeorgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaleb Assefa","family":"Berhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sewale","family":"Anagaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henok","family":"Fisseha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"4776_CR1","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low-and middle-income countries. 2024."},{"issue":"2","key":"4776_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","volume":"156","author":"TF Baumert","year":"2019","unstructured":"Baumert TF, et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156(2):431\u201345.","journal-title":"Gastroenterology"},{"issue":"4","key":"4776_CR3","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","volume":"22","author":"R Gonz\u00e1lez-Grande","year":"2016","unstructured":"Gonz\u00e1lez-Grande R, et al. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4776_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5152\/tjg.2020.19273","volume":"31","author":"O \u00d6zdo\u011fan","year":"2020","unstructured":"\u00d6zdo\u011fan O, et al. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent? Turkish J Gastroenterol. 2020;31(5):384.","journal-title":"Turkish J Gastroenterol"},{"issue":"11","key":"4776_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/kjm2.12275","volume":"36","author":"CF Huang","year":"2020","unstructured":"Huang CF, et al. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36(11):920\u20138.","journal-title":"Kaohsiung J Med Sci"},{"issue":"9","key":"4776_CR6","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/jcm9092702","volume":"9","author":"C Graf","year":"2020","unstructured":"Graf C, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis. J Clin Med. 2020;9(9):2702.","journal-title":"J Clin Med"},{"issue":"3","key":"4776_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.5009\/gnl.2011.5.3.356","volume":"5","author":"ES Jang","year":"2011","unstructured":"Jang ES, et al. The effect of antiviral therapy on serum cholesterol levels in chronic hepatitis C. Gut Liver. 2011;5(3):356.","journal-title":"Gut Liver"},{"issue":"1","key":"4776_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12879-021-06053-3","volume":"21","author":"MG Quaranta","year":"2021","unstructured":"Quaranta MG, et al. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. BMC Infect Dis. 2021;21(1):413.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"4776_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","volume":"73","author":"EC Verna","year":"2020","unstructured":"Verna EC, et al. DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73(3):540\u20138.","journal-title":"J Hepatol"},{"issue":"11","key":"4776_CR10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","volume":"24","author":"M Noureddin","year":"2018","unstructured":"Noureddin M, et al. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol. 2018;24(11):1269.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"4776_CR11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/MEG.0000000000000963","volume":"29","author":"MS Mohamed","year":"2017","unstructured":"Mohamed MS, et al. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. Eur J Gastroenterol Hepatol. 2017;29(12):1368\u201372.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"4776_CR12","first-page":"104","volume":"20","author":"H Soliman","year":"2020","unstructured":"Soliman H, et al. Predictors for fibrosis regression in chronic HCV patients after the treatment with DAAS: results of a real-world cohort study. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune. Endocr Metabolic Disorders). 2020;20(1):104\u201311.","journal-title":"Endocr Metabolic Disorders)"},{"issue":"12","key":"4776_CR13","doi-asserted-by":"publisher","first-page":"e0209615","DOI":"10.1371\/journal.pone.0209615","volume":"13","author":"N Kawagishi","year":"2018","unstructured":"Kawagishi N, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE. 2018;13(12):e0209615.","journal-title":"PLoS ONE"},{"issue":"1","key":"4776_CR14","doi-asserted-by":"publisher","first-page":"8740157","DOI":"10.1155\/2021\/8740157","volume":"2021","author":"BT Tesfaye","year":"2021","unstructured":"Tesfaye BT, et al. Chronic Liver Disease in Ethiopia With a Particular Focus on the Etiological Spectrums: A Systematic Review and Meta-Analysis of Observational Studies. Can J Gastroenterol Hepatol. 2021;2021(1):8740157.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"1","key":"4776_CR15","first-page":"8873389","volume":"2021","author":"T Deress","year":"2021","unstructured":"Deress T, et al. Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis. Sci World J. 2021;2021(1):8873389.","journal-title":"Sci World J"},{"issue":"1","key":"4776_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1186\/s12879-016-2090-1","volume":"16","author":"Y Belyhun","year":"2016","unstructured":"Belyhun Y, et al. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16(1):761.","journal-title":"BMC Infect Dis"},{"key":"4776_CR17","unstructured":"Yemisrach C et al. Treatment of Chronic Hepatitis C in Ethiopia: A Prospective Cohort Study. 2022, MJH. pp. 2790\u2009\u2013\u20091378."},{"issue":"5","key":"4776_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.4269\/ajtmh.20-0367","volume":"103","author":"A Sultan","year":"2020","unstructured":"Sultan A, et al. Treatment of hepatitis C genotypes 1 to 5 in sub-Saharan Africa using direct-acting antivirals. Am J Trop Med Hyg. 2020;103(5):2083.","journal-title":"Am J Trop Med Hyg"},{"issue":"9596","key":"4776_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. lancet. 2007;370(9596):1453\u20137.","journal-title":"lancet"},{"key":"4776_CR20","unstructured":"Federal Ministry of Health. National guidelines for prevention and control of viral hepatitis in Ethiopia 2022."},{"issue":"8","key":"4776_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"R Pugh","year":"1973","unstructured":"Pugh R, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646\u20139.","journal-title":"Br J Surg"},{"issue":"2","key":"4776_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464\u201370.","journal-title":"Hepatology"},{"issue":"2","key":"4776_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"A-IHCG Panel","year":"2020","unstructured":"Panel A-IHCG. Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology (Baltimore MD). 2020;71(2):686.","journal-title":"Hepatology (Baltimore MD)"},{"key":"4776_CR24","unstructured":"Disease AA. October. f.t.S.o.L., Infectious Disease Society of America\u2014HCV Guidance. Recommendation for Testing, Managing, and Treating Hepatitis C. Available online: https:\/\/www.hcvguidelines.org\/uniquepopulation\/acuteinfection (accessed on 3 2022), 2022."},{"key":"4776_CR25","unstructured":"Organization WH. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection: policy brief. World Health Organization; 2024."},{"issue":"1","key":"4776_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/HEP.0000000000000842","volume":"81","author":"K Patel","year":"2025","unstructured":"Patel K, et al. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology. 2025;81(1):358\u201379.","journal-title":"Hepatology"},{"issue":"1","key":"4776_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12664-019-00935-w","volume":"38","author":"A Jain","year":"2019","unstructured":"Jain A, et al. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients. Indian J Gastroenterol. 2019;38(1):39\u201343.","journal-title":"Indian J Gastroenterol"},{"issue":"1","key":"4776_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto S, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol. 2018;17(1):64\u201375.","journal-title":"Ann Hepatol"},{"key":"4776_CR29","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3094","volume-title":"Effect of antiviral therapy for HCV on lipid levels","author":"S Mauss","year":"2017","unstructured":"Mauss S, et al. Effect of antiviral therapy for HCV on lipid levels. London, England: SAGE Publications Sage UK; 2017."},{"issue":"46","key":"4776_CR30","doi-asserted-by":"publisher","first-page":"10226","DOI":"10.3748\/wjg.v22.i46.10226","volume":"22","author":"MR Pedersen","year":"2016","unstructured":"Pedersen MR, et al. Genotype specific peripheral lipid profile changes with hepatitis C therapy. World J Gastroenterol. 2016;22(46):10226.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"4776_CR31","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/MEG.0000000000001821","volume":"33","author":"J McPhail","year":"2021","unstructured":"McPhail J, et al. Fibrosis improvement in patients with HCV treated with direct-acting antivirals. Eur J Gastroenterol Hepatol. 2021;33(7):996\u20131000.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4776_CR32","doi-asserted-by":"crossref","unstructured":"Tada T, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti\u2010viral therapy. Volume 47. Alimentary pharmacology & therapeutics; 2018. pp. 1012\u201322. 7.","DOI":"10.1111\/apt.14554"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04776-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04776-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04776-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:03:25Z","timestamp":1778616205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04776-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4776"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04776-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance for this study was obtained from the SPHMMC Institutional Review Board (Ref. No. PM 23\/336, dated December 15, 2022). Formal permission was also secured from the Department of Internal Medicine prior to data collection. All eligible participants provided informed consent after the study objectives were explained. Written consent was obtained from those able to sign; for participants unable to provide a signature, verbal consent was documented by the data collector and witnessed by an independent observer to ensure compliance with ethical standards. Participants were informed that their participation was voluntary and that they could withdraw at any time without consequences. To maintain confidentiality, no personal identifiers were recorded, and all information was kept strictly confidential and used solely for research purposes. The study was conducted from February 1 and July 30, 2023, in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not relevant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}